

## HELEN FISHER STEPS DOWN FROM BARD1 BOARD

**Melbourne, Australia, 25 November 2020:** BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or **Company**) wishes to advise that Non-executive Director, Ms. Helen Fisher, has decided to step down from the Board of BARD1.

Helen has decided that she will focus on new opportunities, as well as on Bio Capital Impact Fund, a fund she founded in 2017 which focuses on innovative and disruptive technologies in the biotech space.

Helen said: "I have enjoyed working with the BARD1 team and with Sienna Cancer Diagnostics prior to its acquisition by BARD1. The new combined company is a stronger company with an exciting technology pipeline, experienced Board and strong management. I leave the company in great hands and wish it tremendous success to change the lives of millions of patients, which will translate into value for its shareholders."

BARD1's Chairman, Geoff Cumming said, "The Board will miss the critical analysis on a broad range of issues that Helen has provided. She has offered valuable guidance on matters of international tax, accounting and a broad range of financial matters. Helen leaves the company with our best wishes for the future."

*Authorised by the Company Secretary, Tony Di Pietro.*

- ENDS -

### COMPANY CONTACTS

**Dr Leearne Hinch**

CEO

E [leearne@bard1.com](mailto:leearne@bard1.com)

M +61 400 414 416

**Dr Geoff Cumming**

Non-executive Chairman

E [geoff.cumming@bard1.com](mailto:geoff.cumming@bard1.com)

M +61 417 203 021

### ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising best-in-class diagnostic solutions for healthcare professionals and patients. The cancer diagnostics portfolio includes the commercialised hTERT test used as an adjunct to urine cytology testing and diagnostic tests in development for ovarian, breast, lung, prostate and pancreatic cancers. For more information on BARD1, see [www.bard1.com](http://www.bard1.com).

### FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.